RDY RDY
Company Profile ↓Company Overview
RDY (RDY) is a publicly traded company listed on with a market capitalization of $10.13B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 11.0% CAGR over the past five years.
Trades at an undemanding P/E of 0.2.
Carries low leverage with a debt-to-equity ratio of 0.21.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $335.93B (+3.2% YoY); net profit $42.85B.
- Trailing 12 Months Year-on-year growth — revenue +3.2%, earnings -24.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.0%, profit CAGR -1.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.96% |
| 1 Year: | 3.19% |
Compounded Profit Growth
| 5 Years: | -1.67% |
| 1 Year: | -24.22% |
Stock Price Performance
| 1 Year: | -11.34% |
| 6 Months: | -11.47% |
| 3 Months: | -7.80% |
| 1 Month: | -16.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.0% over 5 years.
- Generates positive free cash flow.
CONS
- Earnings shrank at -1.7% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 85.45B | 88.05B | 87.27B | 75.16B | 80.70B |
| Cost of Revenue | - | 36.83B | 39.91B | 40.46B | 32.13B | 43.16B |
| Gross Profit | - | 48.63B | 48.14B | 46.81B | 43.03B | 37.54B |
| Operating Expenses | - | 31.79B | 30.27B | 32.48B | 42.21B | 34.51B |
| Operating Income | - | 16.84B | 17.87B | 14.33B | 829.00M | 3.03B |
| EBITDA | - | 24.64B | 24.31B | 21.59B | 8.63B | 12.15B |
| Interest Expense | - | 830.00M | 907.00M | 944.00M | 1.06B | 1.25B |
| Pretax Income | - | 19.05B | 18.35B | 15.43B | 2.00B | 5.53B |
| Tax Provision | - | 4.95B | 4.08B | 3.53B | -216.00M | 1.18B |
| Net Income | - | 14.18B | 14.37B | 12.10B | 2.21B | 4.43B |
| Diluted EPS | - | 17.02 | 17.25 | 14.52 | 2.65 | 5.32 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 245.88B | 279.16B | 325.54B | 335.93B |
| Cost of Revenue | - | 106.54B | 115.56B | 135.11B | 158.67B |
| Gross Profit | - | 139.34B | 163.61B | 190.43B | 177.26B |
| Operating Expenses | - | 80.29B | 98.30B | 118.41B | 127.14B |
| Operating Income | - | 59.05B | 65.31B | 72.01B | 50.12B |
| EBITDA | - | 74.43B | 88.42B | 96.67B | 79.16B |
| Interest Expense | - | 1.43B | 1.71B | 2.83B | 3.74B |
| Pretax Income | - | 60.37B | 71.87B | 76.78B | 54.82B |
| Tax Provision | - | 15.30B | 16.19B | 19.54B | 12.35B |
| Net Income | - | 45.07B | 55.68B | 56.54B | 42.85B |
| Diluted EPS | - | 54.17 | 66.92 | 67.78 | 51.42 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 321.85B | 387.52B | 492.99B | 579.35B |
| Current Assets | - | 204.25B | 248.05B | 250.11B | 301.98B |
| Cash & Equivalents | - | 5.78B | 7.11B | 14.65B | 15.37B |
| Inventory | - | 48.67B | 63.55B | 71.08B | 76.53B |
| Receivables | - | 72.48B | 80.30B | 90.42B | 101.22B |
| Total Liabilities | - | 90.86B | 106.97B | 155.82B | 198.89B |
| Current Liabilities | - | 85.84B | 96.04B | 130.39B | 167.57B |
| Long Term Debt | 3.80B | - | 3.80B | 3.80B | 12.20B |
| Total Debt | - | 13.47B | 20.02B | 46.77B | 77.34B |
| Total Equity | - | 230.99B | 280.55B | 333.39B | 377.06B |
| Shares Outstanding | - | 832.64M | 834.09M | 834.46M | 834.66M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 58.88B | 45.43B | 46.43B | 56.76B |
| Investing Cash Flow | - | -41.37B | -40.28B | -58.08B | -65.51B |
| Financing Cash Flow | - | -26.86B | -3.76B | 18.91B | 8.29B |
| Capital Expenditure | - | -18.87B | -27.43B | -34.40B | -38.42B |
| Free Cash Flow | - | 40.01B | 18.00B | 12.03B | 18.33B |
| Net Change in Cash | - | -9.36B | 1.39B | 7.26B | -468.00M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 56.7% | 58.6% | 58.5% | 52.8% |
| Operating Margin % | - | 24.0% | 23.4% | 22.1% | 14.9% |
| Net Margin % | - | 18.3% | 19.9% | 17.4% | 12.8% |
| ROE % | - | 19.5% | 19.8% | 17.0% | 11.4% |
| ROCE % | - | 25.0% | 22.4% | 19.9% | 12.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RDY
Dr. Reddy's Laboratories Ltd $RDY Shares Purchased by Quantinno Capital Management LP - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPeHVHWkJGcFp4a0FnX25RVkVuR0VTOVU3Z2Zyb3hwUE00UHBXZXU5eGxsZmcwdnJlbGlObGpvMW1VbFViZXNuWE8zN0NYSnN4aWMteWNVUlA5OFpScnl4RXlmRjZOaEh3QkRuSnc2UGhBS0tVc3RGQkM2NWRBcWpRTENwVE9qM2sxWklLRE…
Bridion, with $1.6B in U.S. sales, gets a generic drug - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPUmZ6Z3FKUnVGQngwTjZpVTF3SmxHZzVfQzJvR254bEkyM0NWM1VWOTZxOVBHc29PdjZhVVM1WTV3OU5BMjh2enIwa09jZzhPeHJ4ZFp5ZDdOa2xpemFUdXdKY1F1RUZOaDRDMHVFUnMtWEkySm9FZmhJLXIyV3RPT3lhNkZCd214M3ptZX…
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky - Morningstar
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQS2tTVlpKV0wycnc5UVZzS0ZaTkdVS0dLQVJXRGxvRWJJTDVIdDhrVmtFekdoZmhYV09hSGU4TkFoSXJ3dU55eERaclM1dHhFUlFweUs2QzUwRGV1Z0xXSHQ3Nk1rTGcyamMtUWJEMm94dHhjaDdLYTROcm8xaXZXRS1meDBUcWZVdnZ6aX…
Dr. Reddy's Laboratories (RDY) Stock Falls on Q4 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOdmQxZEc4eF9SLTJBZW56Ul9OSDBtb1RVRU5ZWHFZMldxZ0tDYW50dE80NVBZdHBRYTRMbHM4cE51WnJfZkpxSEcxc0Y4cS1NTDk3TERTcEtZeTI1bE9ZejZVbGJNQlVsY2tvZXcwNUNHR2owbV9rQmJxeHItYXE1eV96OXJ2T1BjT2xQeE…
Precision Trading with Dr. Reddy's Laboratories Ltd (RDY) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxOSmNHY0ttVmlNQjVLdHR1djZLdlkwcE5ranliZW5yYkdNeEpfeXpILUhQcjBESHBOdDBvOU9JQjZoZ3ZvUzFZV3JaM0N0cFJjUDQxZkRyUHYyVzRscWh4aUpTYV9yanF6RlY2TFJ4blpsVDM3YkFfVUltaHV0Zk1nUGtXZkVud3I4Z0hoeD…
Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY) - PR Newswire
<a href="https://news.google.com/rss/articles/CBMimwJBVV95cUxNdkdWOXFnMFNjcUh6T0s1X1dJVzJfRVc1VzBBZWcwVkNoeF80T3NsSGhNaDhqYzJCU05seXZ4UmhrcmxMOVdBQ093TGhIOUMwaTZpMXREWnhpdWRxaDcyYWlkanIwcUM1WG05MEpENnlnWG4zcXR4UXdna2xOOXo1ZEFxVnpqYkRHR2IxZn…
RDY — Frequently Asked Questions
What is the current share price of RDY?
As of 2026-08-05 17:25 PDT, RDY trades at $12.14 on NASDAQ/NYSE. Its 52-week range is $11.30 to $15.27.
What is the market capitalisation of RDY?
RDY has a market capitalisation of $10.13B on NASDAQ/NYSE.
What is the P/E ratio of RDY?
RDY trades at a trailing price-to-earnings (P/E) ratio of 0.24. Its price-to-book (P/B) ratio is 0.03.
What is the return on equity (ROE) of RDY?
RDY has a return on equity (ROE) of 11.36%. Its return on capital employed (ROCE) is 12.17%.
Is RDY a good stock to buy?
This page provides a data-driven analysis of RDY, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.